Canine Lymphoma: Welfare Through Treatment and Palliation
Canine lymphoma is one of the most common dog cancers — understanding welfare implications of treatment versus palliation helps owners make compassionate decisions.
Key Facts
- Lymphoma accounts for approximately 7-24% of all canine cancers
- Multi-agent chemotherapy (CHOP protocol) achieves remission in 80-90% of dogs with B-cell lymphoma
- Median survival with CHOP is 12-13 months, with some dogs living 2+ years
- Dogs generally tolerate chemotherapy better than humans — most maintain quality of life during treatment
- Without treatment, median survival is 4-6 weeks from diagnosis
Welfare Considerations
Canine lymphoma welfare decisions involve balancing treatment burden against quality of life benefit. The good news is that dogs typically tolerate chemotherapy much better than humans — nausea, lethargy, and appetite loss occur in a minority of patients and are usually manageable. For most dogs achieving remission, quality of life during treatment is good, and the significant survival extension is welfare-positive. For owners unable or unwilling to pursue chemotherapy, palliative corticosteroid treatment extends comfortable life by 4-8 weeks with minimal treatment burden. Welfare assessment throughout — monitoring appetite, activity, and comfort — guides decision-making about continuing, modifying, or stopping treatment. The decision to pursue palliative care over curative intent is always ethically valid.
What You Can Do
- Consult a veterinary oncologist to fully understand treatment options, costs, and realistic outcomes
- Use the HHHHHMM quality of life scale (Hurt, Hunger, Hydration, Hygiene, Happiness, Mobility, More good days) to track welfare
- Know that palliative corticosteroid treatment is a compassionate, valid alternative to chemotherapy
- Discuss with your veterinarian whether each chemotherapy cycle is maintaining quality of life
- Plan end-of-life care proactively — having a plan reduces crisis decision-making and preserves dignity